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ApoptosisIntracellular schizonts of the apicomplexans Theileria annulata and Theileria parva immortalize bovine
leucocytes thereby causing fatal immunoproliferative diseases. Buparvaquone, a hydroxynaphthoqui-
none related to parvaquone, is the only drug available against Theileria. The drug is only effective at
the onset of infection and emerging resistance underlines the need for identifying alternative compounds.
Current drug assays employ monitoring of proliferation of infected cells, with apoptosis of the infected
host cell as a read-out, but it is often unclear whether active compounds directly impair the viability
of the parasite or primarily induce host cell death. We here report on the development of a quantitative
reverse transcriptase real time PCR method based on two Theileria genes, tasp and tap104, which are both
expressed in schizonts. Upon in vitro treatment of T. annulata infected bovine monocytes with
buparvaquone, TaSP and Tap104 mRNA expression levels signiﬁcantly decreased in relation to host cell
actin already within 4 h of drug exposure, while signiﬁcant differences in host cell proliferation were
detectable only after 48–72 h. TEM revealed marked alterations of the schizont ultrastructure already
after 2 h of buparvaquone treatment, while the host cell remained unaffected. Expression of TaSP and
Tap104 proteins showed a marked decrease only after 24 h. Therefore, the analysis of expression levels
of mRNA coding for TaSP and Tap104 allows to directly measuring impairment of parasite viability.
We subsequently applied this method using a series of compounds affecting different targets in other api-
complexan parasites, and show that monitoring of TaSP- and Tap104 mRNA levels constitutes a suitable
tool for anti-theilerial drug development.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Apicomplexan parasites are responsible for a variety of diseases
in humans, pets and/or farm animals, and are thus of considerable
medical and economic importance. Those most relevant for farm
animals are Babesia, Besnoitia, Cryptosporidium, Eimeria, Neospora,
Sarcocystis, Theileria, and Toxoplasma, causing diseases of great
socio-economic impact worldwide. Treatment options for many
of these diseases are limited, and include either culling of infected
livestock, prevention of infection by vaccination, and/or chemo-
therapy (Müller and Hemphill, 2013a).
Theileria parasitize white blood cells. The most important spe-
cies are Theileria parva and Theileria annulata, which cause an acuteand usually fatal lymphoproliferative disease in cattle (Morrison
and McKeever, 2006). Following transmission by ticks, T. parva
sporozoites invade lymphocytes, and T. annulata infect monocytes,
macrophages, dendritic cells and B cells, and, within a few days,
develop into schizonts. Development of schizonts causes host cells
to undergo proliferation (Dobbelaere et al., 1988). This leads to
expansion of the infected cell population and dissemination via
the lymphoid system. Cattle in some endemic areas exhibit a
degree of innate resistance with low mortality, while cattle intro-
duced from outside succumb to the infection rapidly (Boulter and
Hall, 1999).
An important feature of Theileria infections is that the host cells
are ‘immortalize’ upon infection and resume proliferation
(Dobbelaere and Heussler, 1999). Thus, continuous cultures of
T. annulata could be established by infecting peripheral blood
mononuclear cells (PBMCs) with sporozoites (Preston et al.,
1998). T. parva schizont-infected lymphoblastoid cultures were
Table 1
Overview of primers used in this study.
Gene Accession-no. Primer Sequence
Ta18S KF429795.1 Ta18S_F GACCTTAACCTGCTAAATAGG
Ta18S_R CAGGCCTCTCGGCCAAGG
Tap104 TA08425 Tap104_F TCATAGGTCTACAGAACTGGA
Tap104_R TTTAGGTGGTTCTGGACCCT
TaSP TA17315 TaSP_F AGCAGCCCCTTGTCATGGG
TaSP_R TAATAGCTTTTGCACGGAGGA
Actin NM_001100 a-AC1 GAGACCACCTACAACAGCATCATG
a-AC2 CACCTTGATCTTCATGGTGCTGGG
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and by infecting PBMC with T. parva sporozoites (Shkap and
Pipano, 2000). These in vitro systems are the most important tools
to prepare sufﬁcient amounts of the parasite for genome sequenc-
ing (Pain et al., 2005) and to study the developmental processes
such as invasion of host cells by sporozoites (Shaw, 2003), interac-
tions with the host cell (Heussler and Stanway, 2008) with a focus
on the mechanisms of immortalization of the host cell by the par-
asite (Heussler et al., 2002).
To control bovine theileriosis, three strategies are currently
employed: (i) control of the ticks by acaricides, which is expensive,
causes environmental damage, and leads to resistance develop-
ment; (ii) vaccination strategies based on either infection-and-
treatment method or attenuated live vaccines, which have been
extensively reviewed especially with regard to their risks
(McKeever and Morrison, 1998; McKeever, 2007, 2009); and (iii)
chemotherapy, which currently represents the most promising
anti-theilerial strategy.
Buparvaquone, a hydroxynaphthoquinone related to parvaqu-
one, is the only drug available against Theileria, and is a potent
selective inhibitor of mitochondrial electron transport, speciﬁcally
at Complex III (b–c1 complex), in Theileria, but also Plasmodium,
Eimeria and Toxoplasma (Hudson et al., 1985; Fry and Pudney,
1992). Cattle infected with T. annulata or T. parva are cured within
a few days by a single dose injection (McHardy and Morgan, 1985).
The compound has to be administrated, however, during the early
stage of infection to avoid the destruction of the immune system
that occurs during the advanced stages of the disease. Moreover,
ﬁrst cases of resistance against buparvaquone have been reported
(Mhadhbi et al., 2010; Shariﬁyazdi et al., 2012). The mode of action
and the mechanisms of resistance formation are still unknown.
Upon killing the Theileria schizont, the infected cell loses its trans-
formed phenotype and rapidly succumbs to apoptosis, making it
difﬁcult to distinguish between host cell-mediated effects and
the direct action of a given compound upon the parasite (Küenzi
et al., 2003).
There is an urgent need for new drugs to treat bovine theilerio-
sis. Before setting up a suitable screening strategy, however, it is
paramount to be able to distinguish whether a drug acts primarily
against the parasite, or whether it mainly affects the proliferative
host cell. The former represents the ideal chemotherapeutic sce-
nario, since the inactivation of the parasite will restore apoptosis
of the host cell. In the latter case, chances are high that the drug
will affect a host cell target, and adverse side effects are more likely
to occur.
In this study we present a quantitative reverse transcriptase
real time PCR protocol that allows rapid and reliable monitoring
of direct effects upon the Theileria metabolism by comparing the
mRNA levels of two major schizont-surface proteins, namely TaSP
and Tap104 (Witschi et al., 2013; Woods et al., 2013), to host
mRNA levels in buparvaquone treated T. annulata infected macro-
phages. Results were conﬁrmed by showing that buparvaquone
directly affects the structural integrity of the parasite but not host
cell, within few hours of treatment. We subsequently applied this
method using a series of compounds affecting different targets in
other apicomplexan parasites.
2. Materials and methods
2.1. Tissue culture media, biochemicals, and drugs
If not otherwise stated, all tissue culture media were purchased
from Gibco-BRL (Zürich, Switzerland), and biochemical reagents
were from Sigma (St. Louis, MO). Kits for molecular biology were
purchased from Qiagen (Hilden, Germany). Buparvaquone
(McHardy and Morgan, 1985) was provided by Cross VetpharmGroup Limited (Dublin, Ireland), and was kept as 1.5 mM stock
solution in dimethyl sulfoxide (DMSO) at 20 C. Tetracycline
(Sato and Wilson, 2005), clindamycin (Fichera and Roos, 1997),
trans-iodo-boranyl-chalcone (TIBC) (Hayashida et al., 2013) and
ciproﬂoxacin (Lizundia et al., 2009) were purchased from Sigma–
Aldrich (Buchs, Switzerland). All compounds were kept as
100 mM stock solutions in dimethyl sulfoxide (DMSO) at 20 C,
except ciproﬂoxacin which was stored in water (pH 4.5) at
20 C. The dicationic compounds DB745 and DB750 (Schorer
et al., 2012), the artemisinine derivatives artemiside and artemi-
sone (Dunay et al., 2009), and the thiazolide nitazoxanide
(Esposito et al., 2007b) were stored as above.
2.2. Culture of bovine macrophages infected with T. annulata
T. annulata infected bovine macrophages (TaC12 cells) were cul-
tured as described (von Schubert et al., 2010). For drug treatment
experiments, TaC12 cells were seeded into 75 cm2 culture ﬂasks,
treated with the compound or respective amounts of DMSO as a
control and harvested at various time points. Each experimental
treatment was carried out in quadruplicate (4 different ﬂasks),
and these experiments were repeated at least twice to ensure
reproducibility. Cells were detached by removing the medium
and resuspending the cell layer in 1 ml of PBS containing 1 mM
EDTA. Then, the number of viable cells was counted using a 0.4%
trypan blue solution, cells were pelleted by centrifugation (300g,
5 min, 4 C), immediately frozen in liquid nitrogen and stored at
80 C for subsequent DNA, RNA and protein puriﬁcation.
2.3. Processing of samples for quantitative PCR
Simultaneous DNA, RNA, and protein puriﬁcation was per-
formed using a Qiagen Allprep DNA/RNA/protein kit according to
the standard protocol suitable for cell cultures provided by the
manufacturer. DNA was eluted in 100 ll elution buffer from the
kit and diluted 20 times in water prior to analysis by quantitative
PCR.
RNA was puriﬁed including a DNase I digestion (to remove
residual genomic DNA) according to the instructions provided by
the manufacturer, eluted with 40 lL of RNase-free water, quanti-
ﬁed by measuring the absorption at 260 nm, and stored at 80 C.
2.4. Quantitative real-time PCR
Issuing from previously published results (Ros-García et al.,
2012), real-time PCR on DNA was performed using the primers
Ta18S-F and Ta18S-R (Table 1). As external standards, samples
containing between 10 and 104 copies of the plasmid containing
the 18S-fragment were included. For this purpose, the 18S frag-
ment was ampliﬁed from T. annulata genomic DNA and cloned into
the vector pCRBluntII (Invitrogen, Carlsbad, Ca) according to the
manufacturer’s instructions. Synthesis of cDNA for quantitative
RT-PCR was performed with 2 lg of RNA using the Qiagen Omni-
script™ kit with random primers according to the manufacturer’s
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(diluted 1:50 in water) using the Quanti TectTM SYBR Green PCR
Kit (Roche, Basel, Switzerland) in 20 lL standard reactions contain-
ing 0.5 lM of forward and reverse primers (MWG Biotech, Ebers-
berg, Germany). Furthermore, control PCRs with RNA equivalents
from samples that had not been reverse transcribed into cDNA
(data not shown) conﬁrmed that no DNA was ampliﬁed from any
residual genomic DNA that might have resisted DNase I digestion
(see above). PCR was started by initiating the ‘Hot-Start’ Taq
DNA-polymerase reaction at 95 C (10 min). Subsequent DNA
ampliﬁcation was performed in 40 cycles including denaturation
(94 C for 15 s), annealing (58 C for 30 s; 54 C for actin) and
extension (72 C for 30 s); temperature transition rates in all cycle
steps were 20 C/s. Fluorescence was measured at 76 C (Ta18S,
TaSP, Tap104) or 81 C (Act) on a Corbett cycler (Corbett Research,
Mortlake, Australia). From the quantitative RT-PCR, mean values
(±SE) from four biological replicates (independent experiments)
were assessed and expression levels were given as values in arbi-
trary units relative to the amount of actin RNA (Müller et al.,
2007; Müller and Hemphill, 2011). Actin was chosen as a tran-
scribed reference gene based on previous results with Neospora
caninum infected mice (Strohbusch et al., 2008a) and human ﬁbro-
blasts (Müller and Hemphill, 2011). The results of one out of three
independent experiments are shown, all yielding essentially iden-
tical results.
2.5. Immunoﬂuorescence and immunoblotting
For immunoﬂuorescence, TaC12 cells were seeded on cover-
slips, treated and harvested as indicated and processed as
described previously (von Schubert et al., 2010). The antibodies
used in this study are summarized in Table 2.
For immunoblotting, protein pellets obtained from the process-
ing of the samples via the Allprep kit were resuspended in the pro-
tein resuspension buffer included in the kit (104 cells/ll), sonicated
for 5 s at 20 mA, and heated for 20 min at 60 C with shaking. The
proteins were separated by SDS–PAGE and blotted on nitrocellu-
lose as described (Nillius et al., 2011). The blots were decorated
with mouse anti-p104 (1C12) or mouse monoclonal anti-a-tubulin
(DM1A) followed by goat-anti-mouse secondary antibodies conju-
gated to horseradish peroxidase. Chemoluminescence pictures
were detected by a CCD (cooled charge coupled devices) camera.
2.6. Transmission electron microscopy (TEM)
For TEM, conﬂuent cultures of bovine macrophages infected
with T. annulatawere treated with buparvaquone (150 nM) or with
DMSO as a solvent control. Cells were harvested as described above
and resuspended in 1 ml ice-cold 100 mM sodium cacodylate buf-
fer pH 7.3, transferred to 1.5 ml Eppendorf tubes, and centrifuged
(300g, 5 min, 4 C). Pellets were resuspended in 100 mM cacodyl-
ate (pH 7.3) containing 1% glutaraldehyde and ﬁxed overnight atTable 2
Overview of antibodies used in this study.
Antibody Target
Rabbit anti-TaSP T. annulata schizont surface protein TaSP
Mouse 1C12 T. annulata schizont surface protein p104
Mouse DM1A Alpha-tubulin
Goat-anti-rabbit Alexa ﬂuor 488 Rabbit IgG
Goat-anti-mouse Texas red Mouse IgG
Rabbit-anti-mouse-HRP Mouse IgG
IF, immunoﬂuorescence; WB, Western blot.4 C. Pellets were then washed three times in 100 mM cacodylate
buffer and postﬁxed in 100 mM cacodylate containing 2% osmium
tetroxide for 1 h at room temperature. Pellets were then washed
two times in distilled water, contrasted in saturated uranyl acetate
for 30 min, dehydrated in an ethanol series (30%, 50%, 70%, 90%,
3  100%), and embedded in Epon 820 resin (16). The resin was
polymerized at 65 C over a period of 48 h. Ultrathin sections were
cut on a Reichert and Jung ultramicrotome and loaded onto 300-
mesh copper grids (Plano GmbH, Marburg, Germany). Staining
with uranyl acetate and lead citrate was performed as described
previously (Hemphill and Croft, 1997). Finally, grids were viewed
on a Phillips 400 transmission electron microscope operating at
60 kV.
2.7. Statistics
Statistical analysis of the results was performed with suitable
tools from the open source software package R (R Core Team,
2012). Differences exhibiting p values of <0.01 were considered
signiﬁcant.
3. Results
3.1. Assessment of T. annulata 18S RNA expression during
buparvaquone treatment reveals anti-proliferative effect
In order to determine whether the quantitative assessment of
RNA expression could be used to investigate drug effects in T.
annulata, we employed the Ta18S-PCR previously developed for
diagnostic purposes (Ros-García et al., 2012). T. annulata infected
TaC12 cells were cultured in the presence of buparvaquone
(150 nM) or the corresponding amount of DMSO as a control. Cells
were harvested at various time points (0–48 h), counted, and in
parallel the corresponding number of 18S copies was determined
by quantitative PCR. Within the time frame of 30 h, the live cell
numbers in treated and control cells did not differ substantially,
and signiﬁcant differences in cell numbers were noted earliest
after 48 h (Fig. 1A). Conversely, Ta18S RNA expression in control
cells started to increase signiﬁcantly already after 6 h and reached
a plateau at 30 h, whereas corresponding expression levels
remained at a constantly low level in buparvaquone treated cells
(Fig. 1B). Thus, monitoring Ta18S-RNA expression represents a
suitable tool to assess the anti-proliferative effects of buparvaqu-
one against T. annulata schizonts, and picks up these effects much
earlier than monitoring host cell proliferation.
3.2. Assessment of mRNA expression coding for the two T. annulata
schizont proteins TaSP and Tap104 reveals early metabolic
impairment of parasites during buparvaquone treatment
TaC12 cells were treated with buparvaquone (150 nM) or DMSO
as a control, and were harvested at different time points (2 h, 4 h,Dilution Source
1:1000 IF Isabel Roditi, University of Bern, Switzerland
1:200 IF Brian Shiels, University of Glasgow, United Kingdom
1:250 WB
1:5000 IF SIGMA
1:5000 WB
1:1000 IF Molecular probes
1:1000 IF Molecular probes
1:2000 WB DAKO
Fig. 1. Growth of TaC12 cells in the presence of buparvaquone. 107 cells were
seeded at time point 0 in the presence of buparvaquone (150 nM) or equal amounts
of DMSO (control). At various time points, cells were harvested, live cells were
counted, and in parallel Ta18S-rRNA copy number was quantiﬁed by real-time PCR
on genomic DNA. Mean values (±SE) for four biological replicates are presented.
Values labeled by an asterisk are signiﬁcantly different (p < 0.01) between controls
and buparvaquone treated samples. (A) Cell number; (B) 18S copy number.
Fig. 2. Buparvaquone induces a rapid decrease of T. annulatamRNA levels. 107 cells
were seeded at time point 0 in the presence of buparvaquone (150 nM) or equal
amounts of DMSO (control). At various time points, cells were harvested, RNA was
extracted, and mRNA levels of TaSP (A) and Tap104 (B) was quantiﬁed by real-time
RT-PCR to host-cell actin. Mean values (±SE) for four biological replicates of one
representative experiment are presented. All assays were repeated at least twice
yielding essentially identical results. Values labeled by an asterisk are signiﬁcantly
different (p < 0.01) between controls and buparvaquone treated samples.
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schizont-speciﬁc surface proteins TaSP and Tap104 were deter-
mined in relation to host cell actin mRNA by quantitative reverse
transcription real time PCR. Upon buparvaquone treatment, the
relative TaSP mRNA levels decreased rapidly, within 2–6 h, to back-
ground levels (Fig. 2A). Similar results were obtained for Tap104
mRNA (Fig. 2B). As in previous studies (Strohbusch et al., 2008a;
Müller and Hemphill, 2011), actin revealed to be a suitable refer-
ence. In the time frame shown in Fig. 2, mean actin Ct values were
23.6 with a standard deviation of only 0.2 (data not shown). In par-
allel, protein samples were collected and immunoblot analysis of
Tap104 was performed, while alpha-tubulin was analyzed as a
loading control. As shown in Fig. 3A, 24 h of buparvaquone treat-
ment was required before a slight decrease of Tap104 expression
was noted. The expression of Theileria TaSP and host cell alpha-
tubulin during buparvaquone treatment was also investigated by
immunoﬂuorescence, over a time frame of 72 h (Fig. 3B). In
untreated control cultures all TaC12 cells exhibited an intact
microtubular cytoskeleton and, schizonts could be readily visual-
ized in virtually all cells by detection of TaSP during 72 h of culture.In buparvaquone treated TaC12 cells, TaSP staining was still
present after 24 h in most cells, and a reduction of TaSP staining
intensity could be noted earliest after 48–72 h (Fig. 3B). Immuno-
ﬂuorescence labeling employing an antibody directed against
Tap104 yielded essentially identical results. Thus, buparvaquone
treatment induces a rapid loss of TaSP- and Tap104-mRNA expres-
sion, while on the protein level these two antigens are maintained
and still readily detectable for extended periods of time.
3.3. Electron microscopy reveals rapid effects of buparvaquone
treatment on Theileria schizonts within the same time frame as
quantitative reverse transcriptase real time PCR
TaC12 cells treated with buparvaquone (150 nM) or DMSO as a
control were harvested at different time points (2 h, 6 h and 24 h)
and ﬁxed and processed for TEM analysis. In control cells (Fig. 4A–
D) T. annulata schizonts were readily detected. In contrast to other
apicomplexans, Theileria infected host cells lack a parasitophorous
vacuole and corresponding membrane, thus schizonts reside freely
in the host cell cytoplasm. Typically 2–6 parasite nuclei were
BTap104
α-Tub
C C
0 min 2h  4 h  6 h  24 h
BP  C  BP C  BP  C BP
A
Fig. 3. Buparvaquone effects investigated at the protein level. (A) 107 cells were seeded at time point 0 in the presence of buparvaquone (150 nM; BP) or equal amounts of
DMSO as a control (C). At various time points as indicated, cells were harvested and processed for SDS–PAGE followed by immunoblotting. Bands corresponding to alpha-
tubulin (a-Tub) and to Tap104 are shown. (B) Immunoﬂuorescence showing TaC12 cells cultured in the absence (controls) or presence of buparvaquone for 24, 48 and 72 h,
respectively. Cells were stained with antibodies directed against alpha-tubulin (red) and TaSP (green).
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electron dense button-like structures, seemingly acting as mem-
brane connectors and structurally exhibiting some resemblance
to tight junctions, were found to be present within individual
schizonts, or at their periphery. There were no differences between
samples that were ﬁxed and processed just prior to drug treatment
(timepoint 0 h, Fig. 4A and B) and those that were processed for
TEM after 24 h of culture in the absence of buparvaquone
(Fig. 4C and D).
First ultrastructural changes were evident in T. annulata schizo-
nts already after 2 h of drug exposure, and included mainly exten-
sive vacuolization of the schizont cytoplasm. Vacuoles contained
amorphous material of varying electron density and unknown nat-
ure, or intravacuolar membranous indentions were evident (Fig. 4E
and F). The host cell ultrastructure remained unaltered. In many
samples ﬁxed after 6 h of buparvaquone treatment (Fig. 5A and
B), the degree of cytoplasmic vacuolization of schizonts increased,
and accumulation of intravacuolar membrane stacks was often
observed. In addition, many button-like electron-dense structures
found within Theileria schizonts were partially degraded or had
lost their characteristic structure. In other specimens, vacuoles
became rather spacious and occupied large parts of the schizont
cytoplasm (Fig. 5C). After 24 h of buparvaquone treatment, most
parasites were heavily damaged. Nuclei exhibited considerable
shrinkage, electron dense deposits appeared within the nuclear
matrix and also at the schizont periphery adjacent to the host cell
cytoplasm (Fig. 5D–F). In some instances, peripheral button-like
electron dense structures remained associated with the schizont
periphery (Fig. 5D), in other cells (Fig. 5E and F), these structureswere completely lost, and the ultrastructural organization of the
schizonts was considerably distorted. However, in all instances,
the parasite plasma membrane remained morphologically intact
and clearly separated the parasite and host cell cytoplasm. Thus,
electron microscopy demonstrated the rapid parasite-speciﬁc
effects of buparvaquone and largely mirrored the results obtained
by quantitative TaSP- and Tap104-reverse transcriptase real time
PCR.
3.4. Assessment of a range of anti-parasitic compounds employing
quantitative TaSP and Tap104 reverse transcriptase real time PCR
Monitoring of mRNA expression levels of TaSP and Tap104 was
employed to investigate a selection of compounds against T. annu-
lata schizonts. Artemisone and artemiside, DB745, DB750, and
nitazoxanide have been shown earlier to exhibit in vitro activities
against other apicomplexan parasites such as Toxoplasma gondii
and N. caninum in the micromolar and submicromolar range
(Esposito et al., 2007b; Dunay et al., 2009; Kropf et al., 2012;
Mazuz et al., 2012; Schorer et al., 2012), ciproﬂoxacine and clind-
amycine target Plasmodium and Theileria apicoplast constituents
such as topoisomerase II and large subunit rRNA, and tetracycline
acts on the small subunit rRNA of the plastid (Lizundia et al., 2009).
TIBC was reported to markedly inhibit proliferation of T. parva-
infected lymphocytes by speciﬁcally inhibiting MDM2
(Hayashida et al., 2013). The results, summarized in Table 3, show
that several compounds had a marked effect on proliferation of
host cells after 3 days of culture, such as DB750 and DB745 (used
at 1 lM), the two artemisinine derivatives (used at 10 lM), as well
AB
C
D
E F
n
n
n
n
n
mito
mito
N
N
N
mito
mito
n
v
v
n
mito
mito
Fig. 4. Buparvaquone treatment affects the structural integrity of T. annulata schizonts at at early timepoint. (A)–(D) show samples of non-treated control cells ﬁxed and
processed at timepoint 0 h (A and B) and 24 h (C and D), with (B) and (D) being higher magniﬁcation views of the boxed areas in (A) and (C). (E) Represents a T. annulata
infected cell treated with buparvaquone for 2 h, and the boxed area is enlarged in (F). N = host cell nucleus, mito = host cell mitochondria, n = schizont nucleus, white thin
arrows point towards the schizont-host cell cytoplasm-interface, white triangles indicate button-like electron-dense structures seemingly acting as membrane connectors.
Note the increased vacuolization within the cytoplasm of schizonts in buparvaquone-treated cells (E and F). Bar in A = 3.4 lm, B = 0.8 lm, C = 3.4 lm, D = 0.6 lm, E = 2 lm,
F = 0.6 lm.
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none of these compounds induced a marked change in the TaSP
mRNA expression levels. This indicates that all these compounds,
with the exception of buparvaquone, primarily impair host cell
metabolism, and do not exert their efﬁcacy by interfering with par-
asite metabolic activities in the ﬁrst place.4. Discussion
We here present the development of a sensitive tool, for the
assessment of rapid and parasite-speciﬁc drug activities in TaC12
cells infected with T. annulata schizonts, which is based on the
quantitative monitoring of mRNA coding for the two schizont sur-
face proteins TaSP and Tap104 (Seitzer et al., 2007) in relation to
host cell actin mRNA expression. Both antigens are also expressed
in T. parva schizonts (Schnittger et al., 2002), and a similar assay
could be potentially applied for that parasite as well. There is a
clear need for the identiﬁcation of novel compounds for the treat-
ment of theileriosis. While buparvaquone is widely used and effec-
tive, it has clear limitations such as costs as well as emerging
resistance, which require urgent action.Assessment of the efﬁcacy for drugs in Theileria infected cells is
not a straightforward matter. T. parva-infected lymphocytes and
T. annulata infected macrophages are transformed and undergo
continuous proliferation, and apoptosis of these host cells is
restored once the invaders are killed (Dobbelaere and Heussler,
1999). Different assays have been used to investigate the efﬁcacy
of anti-theilerial drugs. Since elimination of Theileria schizonts will
cause host cell apoptosis, it is possible to simply monitor host cell
proliferation, either microscopically or by metabolic incorporation
of a tracer such as tritiated thymidine (Lizundia et al., 2009).
Microscopy offers the added value of visualizing changes in the
host cell morphology. Other methods include classical vitality
assays 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) or resazurin, but they all have the caveat that not
parasite proliferation, but rather host cell proliferation, is
quantiﬁed (Müller and Hemphill, 2013b).
Most importantly, the assays use to date do not allow to clearly
determine whether a compound affects primarily the parasite or
the host cell, since accurate controls are missing. Non-infected nor-
mal macrophages or B-cells do not naturally proliferate in culture,
or only to a limited extent, and are thus not of use to assess poten-
tial cytotoxic effects. One possibility is to perform drug assays
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Fig. 5. Ultrastructural changes observed after 6 and 24 h of buparvaquone treatment. (A)–(C) show cells processed after 6 h, and (D)–(F) shows specimens processed after
24 h of drug treatment. (A) and (B) (B = higher magniﬁcation view of A) show an increased vacuolization (v) and accumulation of intravacuolar membrane stacks (apv). In
other specimens such as in (C), vacuoles become rather spacious and occupied large parts of the schizont cytoplasm. (D)–(F) show cells processed after 24 h of buparvaquone
treatment, with considerable shrinkage of parasite nuclei (n) and electron dense deposits within the nuclear matrix and also at the schizont periphery adjacent to the host cell
cytoplasm (E) and (F) (at a higher magniﬁcation of E). The button-like electron dense structures remained associated with the schizont periphery in some cells (D, marked
with white triangles), in others cells (Fig. 5E and F), these structures were completely lost. Note that in all instances the parasite plasma membrane (white arrows) remained
intact, and no alterations in the host cell were observed. mito = host cell mitochondria. Bar in A = 3.4 lm, B = 0.5 lm, C = 1 lm, D = 0.6 lm, E = 1.7 lm, F = 0.6 lm.
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bovine macrophages (von Schubert et al., 2010) and/or the non-
infected B-lymphosarcoma cell line BL3 (Moreau et al., 1999).
However, these controls cannot exclude that observed inhibition
of a given compound of Theileria infected cells is due to impairment
of host cell-speciﬁc processes instead of parasite-speciﬁc inhibition
(Lizundia et al., 2009).
Therefore, besides growth or viability assays of treated cells, a
marker should be used that allows detecting effects of the com-
pound on the parasite viability in a time window where the host
cell is still fully intact. Monitoring of RNA expression thus repre-
sents an ideal marker, based on the rationale that intact RNA is
only detectable when viable organisms are present in a given tis-
sue or cells, and transcription is depressed once an organism is
metabolically impaired. This is conﬁrmed in this study where we
showed that the negative impact of buparvaquone on T. annulata
proliferation can be monitored through assessment of 18S RNA
levels in TaC12 cells.Similar assays, albeit by detecting other RNA targets, have been
developed earlier. For instance, one assay based on measuring of
mRNA expression levels of dense granule antigen 2, a protein that
is expressed in both tachyzoites and bradyzoites of N. caninum, has
been used to quantify the viability of this parasite within infected
host cells, and within infected tissue of experimentally infected
animals (Strohbusch et al., 2008a,b; Debache et al., 2009;
Lizundia et al., 2009). More recently, van den Bogaart et al.
reported on the development and application of a duplex quantita-
tive reverse transcriptase PCR for simultaneous assessment of drug
activity against Leishmania intracellular amastigotes and their host
cells, by quantifying Leishmania 18S ribosomal RNA and the human
beta-2-microglobulin mRNA (van den Bogaart et al., 2013). In this
study, we found that buparvaquone treatment of T. annulata
infected cells leads to a rapid and speciﬁc drop in the expression
levels of the two schizont surface antigens TaSP and Tap104mRNA.
This drop is evident already within the ﬁrst 2–4 h of drug exposure,
while TaC12 cells continue proliferation for many more hours
Table 3
Efﬁcacy test against TaC12 cells employing several compounds known to be effective
against various apicomplexan parasites.
Compound Concentration Viable TaC12 (105) TaSP vs. actin
Control 0.1% 32.0 ± 2.2 3.19 ± 0.10
Buparvaquone 150 nM 8.8 ± 1.8⁄ 0.24 ± 0.01⁄
Ciproﬂoxacin 10 lM 33.4 ± 3.0 2.34 ± 0.36
Clindamycine 10 lM 34.0 ± 1.2 2.97 ± 0.09
Tetracycline 20 lM 11.4 ± 3.4⁄ 2.83 ± 0.45
Artemiside 10 lM 2.2 ± 0.2⁄ 5.04 ± 0.21
Artemisone 10 lM 4.6 ± 0.7⁄ 3.39 ± 0.53
Nitazoxanide 10 lM 22.8 ± 3.1 2.64 ± 0.08
DB745 1 lM 0 ± 0⁄ 2.86 ± 0.46
DB750 1 lM 4.2 ± 1.3⁄ 1.72 ± 0.23
TIBC 10 lM 9.0 ± 3.0⁄ 2.70 ± 0.43
TaC12 cells were treated with various compounds or with DMSO as a solvent
control as indicated. Viable cells were counted in the presence of Trypan blue after
3 d or harvested for RNA extraction after 24 h. Mean values (±SE) for four biological
replicates of one representative experiment are presented. All assays were repeated
at least twice yielding essentially identical results. Values labeled by an asterisk are
signiﬁcantly different (t-test; p < 0.001) from the control.
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schizonts is clearly mirrored by electron microscopical observa-
tions that detect obvious signs of metabolic and structural impair-
ment (vacuolization, autophagy-like features) within the same
time window. The progressive deterioration of the schizont ultra-
structure within the ﬁrst 24 h of drug treatment, however, is not
readily reﬂected on the protein level. Alterations in the TaSP and
Tap104 expression levels are not detected prior to 24 h, neither
by light microscopical inspection, Western blotting nor by immu-
noﬂuorescence staining, at a timepoint where many parasites have
undergone distinct ultrastructural changes. Thus, buparvaquone
affects the integrity and thus viability of the Theileria schizont long
before indirect effects on the host cell due to the onset of apoptosis
are visible (Guergnon et al., 2003). Besides the described mode of
action involving mitochondrial electron transport (Hudson et al.,
1985; Fry and Pudney, 1992), this rapid effect may be also partially
due to a reductive activation of the naphthoquinone to the corre-
sponding semiquinone radical directly binding to DNA and thereby
inhibiting replication and transcription as proposed for the mode
of action of some antitumoral quinones (Butler and Hoey, 1987).
Subsequently, we investigated a number of compounds which
have been shown earlier to display pronounced activities against
other apicomplexan parasites. Some of these induced a substantial
depression in cell proliferation within 3 days of culture. The arte-
misinine derivatives artemisone and artemiside exhibited interest-
ing in vitro activities against T. gondii tachyzoites, and were also
proven to act against experimentally induced acute and reactivated
toxoplasmosis in mice (Dunay et al., 2009). Artemisone was also
found to protect gerbils against experimental N. caninum infection
(Mazuz et al., 2012). The nitro-thiazolide nitazoxanide exhibited
pronounced in vitro activity against N. caninum (Esposito et al.,
2007a,b; Mazuz et al., 2012). Interestingly, nitazoxanide was also
found to be highly active against cancer cells such as the colon car-
cinoma cell line Caco2, and this effect was shown to be based on the
interaction of the compound with glutathione-S-transferase Pi
(GSTP1), which is highly expressed in colon cancer cells (Müller
et al., 2008). Thiazolide-induced apoptosis in colorectal cancer cells
is mediated via the Jun kinase-Bim axis and it would be interesting
to investigate whether this also is relevant in Theileria-infected
cells. Pentamide derivatives, such as the two closely related dicat-
ionic compounds DB750 and DB745, previously shown to be highly
effective at 1 lM against N. caninum tachyzoites in vitro and also
efﬁcacious in the experimental mouse model (Debache et al.,
2011; Schorer et al., 2012), did also have a signiﬁcant impact on
TaC12 proliferation. However, as evidenced by quantitative reverse
transcriptase PCR, none of these compounds was primarily target-ing the parasite metabolism, since TaSP mRNA expression levels
were not notably altered after 24 h. Of those compounds that have
been postulated to target the apicoplast, only tetracycline (at
20 lM) showed a marked effect, but again, this was not associated
with a primary action on the parasite metabolism. In contrast to
studies on T. parva (Lizundia et al., 2009), ciproﬂoxacin did not neg-
atively affect neither T. annulata schizont mRNA expression nor the
proliferation of T. annulata-infected cells. However, our investiga-
tions on the effects of ciproﬂoxacin treatment of T. parva infected
lymphocytes conﬁrmed the ﬁndings obtained by Lizundia et al.
(data not shown), demonstrating that there must be some substan-
tial differences between T. parva and T. annulata. However, the
question whether these differences are related to the host cell or
are based on different metabolic requirements of the two parasites
needs to be addressed. Finally, TIBC applied at 10 lM was also
shown to have a profound impact on TaC12 proliferation, but para-
site mRNA expression was not affected, conﬁrming earlier results
that have shown that TIBC interacts with host MDM2 (Hayashida
et al., 2013).
Our results suggest the following strategy for the identiﬁcation
of novel anti-theilerial compounds. In as ﬁrst round, a series of
compounds is tested on TaC12 cells determining growth or a via-
bility parameter (e.g. via a resazurin assay) after a couple of days.
Compounds inhibiting growth are then tested in a second round on
TaC12 cells during 24 h. Then RNA is extracted and TaSP vs. actin
levels are determined. A compound as effective as buparvaquone
(or better) would reduce relative mRNA levels to background val-
ues whereas compounds affecting the host cell would reduce actin
levels to similar extents or even faster than TaSP levels.
Taken together, the method described here does not reveal the
mechanism of action of a compound, but constitutes a promising
tool in the further assessment of drugs for the chemotherapy of
bovine theileriosis.
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